Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian markets open weak
Fri, 13 Nov 09:30 am

Major Asian stock markets have opened the day on a disappointing note. Stock markets in Hong Kong (down 2.1%) and China (down 1.2%) are the top losers in the pack. Major stock indices in Europe and US ended their previous session on a dismal note. The rupee opened trading at 66.34 per US$.

Meanwhile, Indian stock markets have opened the day on a negative note. The BSE-Sensex is trading lower by 266 points (down 1%) and NSE- Nifty is trading lower by 75 points (down 1%). Both, BSE Mid Cap and BSE Mid Cap stocks have opened in red. Both the indices are trading lower by 1.3% and 0.8% respectively. Majority of the sectoral indices have opened the day on a weak note too. Stocks from oil & gas and banking sector are leading losers in the pack.

According to a financial daily, the government data released recently showed weak growth in the Index of Industrial Production (IIP) data. Reportedly, IIP for the month of September rose by 3.6% in as compared to revised 6.2% in August. The growth was impacted due to poor performance in the manufacturing and consumer non-durable sectors.

Further, the Consumer Price Index (CPI) rose to 5% in October as compared to 4.4% in the previous month. The inflation grew mainly on account of rise in the prices of pulses due to domestic shortages. However, generation of electricity grew by 11.4% on a MoM basis. Further capital goods sector which indicates an investment demand in the economy grew by 10.5% on a MoM basis. Reportedly, sales of car too grew by 21.8% in the month of October.

The Nikkei Manufacturing Purchasing Managers Index (PMI) fell to 50.7 in October as compared to 51.2 in the month of September. A number below 50 indicates contraction in demand.

Among the various sectors, the regulatory issues in the Pharma sector have been quite recurrent these days. India's big pharma companies have been facing several challenges on this front. Dr Reddy's has been one of them. The company had recently received warning letter from the US regulator. And things seem to be just worsening further. As per an article in leading financial daily, Dr Reddy's Laboratories has been restrained from selling esomeprazole tablets in the US market. The order is issued by the district court of Delaware, USA.

Esomeprazole, also known as Nexium (brand name) has sales of around US$ 5.2 bn for the 12 months period ended July. The company had received approval couple of months back and was among the early entrants in US market for the drug.

Reportedly, the company stated that it is complying with the order of the Court and is simultaneously evaluating all possible options to resolve the matter at the earliest. Already, the company is facing regulatory issues and the recent order of restraining the sales of esomeprazole will further impact the company's business. It is imperative to note, this could had been quite a lucrative opportunity for the company.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.